References
- Connolly SJ, et al. Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine. 2011 Mar 3; 364(9):806–17.
- Healey JS, et al. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. New England Journal of Medicine [Internet]. 2023 Nov 12. Available from:
https://pubmed.ncbi.nlm.nih.gov/37952132/ - Kirchhof P, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. European Heart Journal. 2018 Mar 20; 39(32):2942–55. DOI: 10.1093/eurheartj/ehy176
- Halvorsen S, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. European Heart Journal. 2014 Feb 20; 35(28):1864–72. DOI: 10.1093/eurheartj/ehu046
- Douglas PS, Patel MR, Bailey SR, Dai D, Kaltenbach L, Brindis RG, Messenger J, Peterson ED. Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography. Journal of the American College of Cardiology. 2011 Aug 16; 58(8):801–9. DOI: 10.1016/j.jacc.2011.05.019
- Knuuti J, Ballo H, Juarez-Orozco LE, et al. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J. 2018; 39:3322–3330. DOI: 10.1093/eurheartj/ehy267
- Tsai WC, Liu YW, Huang YY, Lin CC, Lee CH, Tsai LM. Diagnostic value of segmental longitudinal strain by automated function imaging in coronary artery disease without left ventricular dysfunction. J Am Soc Echocardiogr. 2010 Nov; 23(11):1183–9. DOI: 10.1016/j.echo.2010.08.011
- Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec; 380(9859):2224–60. pmid:23245609
- GATS-2 Fact sheet: International Institute for population sciences (IIPS), Mumbai.
Global adult tobacco survey (GATS, India), 2016–17, New Delhi, Ministry of health and family welfare . Govt of India 2017. - Zhao D. JACC. Asia. 2021; 1:1–13.
- Castellano JM, et al. N. Engl. J. Med. 2022; 387:967–977.
- World Health Organization (WHO).
Web Annex A . World Health Organization Model List of Essential Medicines – 23rd List, 2023. Geneva, 2023. (available athttps://www.phri.ca/wp-content/uploads/2023/07/WHO-MHP-HPS-EML-2023.02-eng.pdf ). - Byrne RA., et al. Eur. Heart J. 2023; 44:3720–3826.
- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020; 76(25):2982–3021. DOI: 10.1016/j.jacc.2020.11.010
- Pillay J, Gaudet L, Wingert A, Bialy L, Mackie AS, Paterson DI, et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. Bmj. 2022; 378. DOI: 10.1136/bmj-2021-069445
- Taegtmeyer H.
Principles of Fuel Metabolism in Heart Muscle . In: de Jong JW, editor, Myocardial Energy Metabolism. Dordrecht/Boston/Lancaster: Martinus Nijhoff Publishers; 1988. pp. 17–34. DOI: 10.1007/978-94-009-1319-6_3 - Neubauer S. The Failing Heart-An Engine Out of Fuel. N Engl JMed. 2007; 356:1140–1151. DOI: 10.1056/NEJMra063052
- Nakamura T, Mizutani J, Ohki K, Yamada K, Yamamoto N, Takeshi M, et al. Casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro improves central blood pressure and arterial stiffness in hypertensive subjects: A randomized, double-blind, placebo-controlled trial. Atherosclerosis. 2011 Nov; 219(1):298–303. DOI: 10.1016/j.atherosclerosis.2011.06.007
- Ishida Y, Shibata Y, Fukuhara I, Yano Y, Takehara I, Kaneko K. Effect of an Excess Intake of Casein Hydrolysate Containing Val-Pro-Pro and Ile-Pro-Pro in Subjects with Normal Blood Pressure, High-Normal Blood Pressure, or Mild Hypertension. Bioscience, Biotechnology, and Biochemistry. 2011 Mar 23; 75(3):427–33. DOI: 10.1271/bbb.100560
- Cicero AF, Rosticci M, Gerocarni B, Bacchelli S, Veronesi M, Strocchi E, et al. Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial. Hypertension Research. 2011 Jul 14; 34(9):1035–40. DOI: 10.1038/hr.2011.92
- de Leeuw PW, van der Zander K, Kroon AA, Rennenberg RMW, Koning MMG. Dose-dependent lowering of blood pressure by dairy peptides in mildly hypertensive subjects. Blood Pressure. 2009 Jan; 18(1–2):44–50. DOI: 10.1080/08037050902761209
- Catlin B, et al
Different perspectives for assigning weights to determinants of health . Wisconsin: County Health Rankings Working Paper. 2010. - McGinnis JM, et al. The Case For More Active Policy Attention To Health Promotion. Health Affairs. 2002; 21(2):78–93. PubMed PMID: 11900188. DOI: 10.1377/hlthaff.21.2.78
- Hamad R, et al. Explaining the Variance in Cardiovascular Disease Risk Factors: A Comparison of Demographic, Socioeconomic, and Genetic Predictors. Epidemiology. 2022; 33(1):25–33. PubMed PMID: 00001648-202201000-00004. DOI: 10.1097/EDE.0000000000001425
- National Center for Health Statistics. 2019
Public-Use Mortality Files . In: Statistics NCHS Washington D.C., USA; 2022. - Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur J Prev Cardiol. 2022; 29(1):216–27. DOI: 10.1093/eurjpc/zwaa167
- To TL, Doan TN, Ho WC, Liao WC. Prevalence of Frailty among Community-Dwelling Older Adults in Asian Countries: A Systematic Review and Meta-Analysis. Healthcare (Basel). 2022; 10(5). DOI: 10.3390/healthcare10050895
- Seeley A, Glogowska M, Hayward G. ‘Frailty as an adjective rather than a diagnosis’-identification of frailty in primary care: a qualitative interview study. Age Ageing. 2023; 52(6). DOI: 10.1093/ageing/afad095
- Chaninda D, Taweesak C, Caputo M, Vohra HA. Current Perspectives on Contemporary Rheumatic Mitral Valve Repair. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. 2021 Sep 3; 16(6):510–6. DOI: 10.1177/15569845211032942
- Chen SW, Chen CY, Chien-Chia Wu V, Chou AH, Cheng YT, Chang SH, et al. Mitral valve repair versus replacement in patients with rheumatic heart disease. The Journal of Thoracic and Cardiovascular Surgery. 2022 Jul 1; 164(1):57–67.e11. DOI: 10.1016/j.jtcvs.2020.07.117
- Fu J, Li Y, Zhang H, Han J, Jiao Y, Du J, et al. Outcomes of mitral valve repair compared with replacement for patients with rheumatic heart disease. The Journal of Thoracic and Cardiovascular Surgery. 2021 Jul 1; 162(1):72–82.e7. DOI: 10.1016/j.jtcvs.2020.01.053
- Jiang Y, Wang C, Li G, Chen S. Clinical outcomes following surgical mitral valve repair or replacement in patients with rheumatic heart disease: a meta-analysis. Annals of Translational Medicine. 2021 Feb 1; 9(3):204. DOI: 10.21037/atm-20-3542
- Kim WK, Kim HJ, Kim JB, Jung SH, Choo SJ, Chung CH, et al. Clinical outcomes in 1731 patients undergoing mitral valve surgery for rheumatic valve disease. Heart. 2017 Nov 16; 104(10):841–8. DOI: 10.1136/heartjnl-2017-312249
- Simpson MT, Kachel M, Neely RC, Erwin WC, Yasin A, Patel A, et al. Rheumatic Heart Disease in the Developing World. Structural Heart. 2023 Sep 19; 100219. DOI: 10.1016/j.shj.2023.100219
- Guidelines. Arquivos Brasileiros de Cardiologia [Internet]. 2009 Sep [cited 2020 Oct 6];93(3). Available from:
https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2009002100001 - Seventy-First World Health Assembly A71/25 Provisional agenda item 12.8 Rheumatic fever and rheumatic heart disease Report by the Director-General [Internet]. 2018. Available from:
https://apps.who.int/gb/ebwha/pdf_files/WHA71/A71_25-en.pdf - TabNet Win32 3.0: SUS Hospital Morbidity – by place of hospitalization – Brazil [Internet]. Datasus.gov.br. 2021. Available from:
http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/niuf.def - TabNet Win32 3.0: SUS Hospital Morbidity – by place of residence – Brazil [Internet]. Datasus.gov.br. 2022. Available from:
http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/nruf.def . - Figueiredo ET de, Azevedo L, Rezende ML, Alves CG, Figueiredo ET de, Azevedo L, et al. Rheumatic Fever: A Disease without Color. Arquivos Brasileiros de Cardiologia [Internet]. 2019 Sep 1; 113(3):345–54. Available from:
https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019000900345&lng=en&nrm=iso&tlng=pt - Beatriz A, Lima R, Barros M, Santos M. Description of the Social Indicators in Adolescents with Rheumatic Fever Description of the Social Markers in Adolescents with Rheumatic Fever. 30. Available from:
http://sociedades.cardiol.br/socerj/revista/2005_01/a2005_v18_n01_art03.pdf - Dangel JH. Cardiovascular changes in children with mucopolysaccharide storage diseases and relate disorders — clinical and echocardiographic findings in 64 patients. Eur J Pediatr. 1998; 157:5348. DOI: 10.1007/s004310050872
- Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, et al. Cardiac disease in patient with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011; 34:1183–97. DOI: 10.1007/s10545-011-9359-8
- Leal GN, de Paula AC, Leone C, Kim CA. Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol Young. 2010; 20:254–261. DOI: 10.1017/S104795110999062X
- Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics. 2007; 120:405–418. DOI: 10.1542/peds.2006-2184